Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell

The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for stage II-IVa resectable esophageal squamous cell carcinoma. The study plans to enroll 114 eligible patients who will be randomly assigned in a 1:1:1 ratio to receive 3 cycles of neoadjuvant immunochemotherapy (pembrolizumab plus albumin paclitaxel and cisplatin;Pembrolizumab plus 5-fluorouracil and cisplatin) or chemotherapy alone (5-fluorouracil and cisplatin), followe

Trial Details

NCT ID
NCT06006650
Phase
PHASE2
Sponsor
Tang-Du Hospital
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
Locations (sample)
  • Xi'an, Shaanxi, China|34.25833,108.92861
  • Xi’an, Shanxi, China|35.99785,113.52486
  • Xi'an, China|34.25833,108.92861

Key Eligibility Criteria

  • Pathological diagnosis: esophageal squamous cell carcinoma. 2.18-75 years old; 3.Clinical stage II-IVa; 4.no prior antitumor therapy, such as immun…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →